Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.46 |
| ▸ | CLK2 | P49760 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.42 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29585632 | 1.00 | TRPV1 (0.49) | TRPV1USP30TRPV4CYP2C9SLC22A6 | |
| SCHEMBL27832974 | 0.86 | KCNQ3 (0.42) | TRPV1USP30KCNQ3KCNQ2KCNE1 | |
| SCHEMBL21341996 | 0.84 | ALDH1A1 (0.52) | TRPV1USP30TRPV4CYP2C9SLC22A6 | |
| SCHEMBL9906890 | 0.84 | KDM4E (0.55) | TRPV1USP30CYP2C9SLC22A6SLC22A8 | |
| SCHEMBL15540776 | 0.83 | TRPV1 (0.44) | TRPV1USP30TRPV4CYP2C9SLC22A6 | |
| SCHEMBL23213553 | 0.82 | P4HTM (0.45) | TRPV1KCNQ3KCNQ2 | |
| SCHEMBL24974096 | 0.81 | MAPT (0.50) | TRPV1USP30CLK2DYRK1AEPHX2 | |
| SCHEMBL3573330 | 0.81 | SMN1; SMN2 (0.47) | TRPV1USP30CYP2C9SLC22A6SLC22A8 | |
| SCHEMBL28940981 | 0.81 | P4HTM (0.41) | TRPV1KCNQ3KCNQ2KCNJ11 | |
| SCHEMBL20097426 | 0.80 | ATM (0.53) | TRPV1USP30EPHX2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | claimed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | claimed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | claimed |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | claimed |
| EP-3484878-B1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | claimed |
| EP-3484894-B1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-19 | — | — | EP | claimed |
| EP-3484894-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-05-22 | — | — | EP | claimed |
| CN-109689664-A | The quinoline and azepine quinoline compound that tricyclic heteroaryl as PAR4 inhibitor replaces | 百时美施贵宝公司 | 2019-04-26 | — | — | CN | claimed |
| WO-2018013776-A1 | TRICYCLIC HETEROARYL-SUBSTITUTED QUINOLINE AND AZAQUINOLINE COMPOUNDS AS PAR4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-01-18 | — | — | WO | claimed |
| WO-2024101172-A1 | (HETERO)ARYL UREA COMPOUND AND INSECTICIDE | 日本曹達株式会社 | 2024-05-16 | — | — | WO | disclosed |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-19 | — | — | US | disclosed |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-16 | — | — | US | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-109689664-B | Tricyclic heteroaryl substituted quinoline and azaquinoline compounds as PAR4 inhibitors | 百时美施贵宝公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2011083278-A1 | NOVEL BENZOIC PYRROLOPYRIDINE DERIVATIVES | LABORATOIRES FOURNIER SA (FR) | 2011-07-14 | — | — | WO | disclosed |
| US-7666873-B2 | N-phenyl-(2R,5S)dimethylpiperazine derivative | ASTELLAS PHARMA INC. (JP) | 2010-02-23 | — | — | US | disclosed |
| US-20080214543-A1 | N-Phenyl-(2R,5S)Dimethylpiperazine Derivative | ASTELLAS PHARMA INC. (JP) | 2008-09-04 | — | — | US | disclosed |
| US-7297698-B2 | N-phenyl-(2R,5S) dimethylpiperazine derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-20 | — | — | US | disclosed |
| US-20050261303-A1 | N-phenyl-(2r,5s) dimethylpiperadine derivative | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
| EP-1557411-A1 | N-PHENYL-(2R,5S)DIMETHYLPIPERADINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261303-A1 | N-phenyl-(2r,5s) dimethylpiperadine derivative | BPHL, QDPR, SRD5A2 | TRPV1 629/4885USP30 1952/4885TRPV4 557/4885 |
| US-11932658-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, PARP14, F2R | TRPV1 1269/4885USP30 4006/4885TRPV4 487/4885 |
| US-11873288-B2 | Inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) | FAAH, FAAH2, EPHX2 | TRPV1 1742/4885USP30 389/4885TRPV4 3259/4885 |
| US-20080214543-A1 | N-Phenyl-(2R,5S)Dimethylpiperazine Derivative | BPHL, AR, SRD5A2 | TRPV1 1240/4885USP30 1894/4885TRPV4 914/4885 |
| US-20210163465-A1 | BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS | F2, F2RL3, F12 | TRPV1 1590/4885USP30 4631/4885TRPV4 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.